|Bid||3.0100 x 900|
|Ask||3.0800 x 800|
|Day's Range||3.0000 - 3.2000|
|52 Week Range||2.7700 - 4.1800|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 18, 2021 - May 24, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Cumberland (NASDAQ:CPIX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 88.89% over the past year to $0.01, which beat the estimate of ($0.01). Revenue of $10,262,000 declined by 24.97% year over year, which beat the estimate of $9,780,000. Outlook Cumberland hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Conference Call Details Date: Mar 09, 2021 View more earnings on CPIX Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/3x85aqjk Price Action 52-week high: $4.30 52-week low: $2.77 Price action over last quarter: Up 12.93% Company Profile Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It focuses on the acquisition, development, and commercialization of branded prescription products. The company provides prescription products to hospital acute care and gastroenterology to address unmet or poorly met medical needs. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox- Pak, Vaprisol and Ethyol. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 9, 2021Cumberland Earnings Preview© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues for the fourth quarter were $10.3 million, up 10% over the prior year period. For the full year 2020, Net Revenues totaled $37.4 million, a 9% increase over 2019. The company also recorded an additional $3.2 million in revenue during the year associated with divested product rights for two brands it is no longer distributing.